Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 2/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564378 | 0.89 | CYP2C9 (0.62) | HTR2BHDAC1HDAC8HDAC6TDP1 | |
| SCHEMBL6202834 | 0.86 | HPGD (0.64) | HTR2BHDAC1HDAC8HDAC6ACHE | |
| SCHEMBL352152 | 0.85 | HPGDS (0.73) | HDAC1HDAC8HDAC6TDP1ACHE | |
| SCHEMBL27768678 | 0.85 | HDAC1 (0.70) | HDAC1HDAC8HDAC6TDP1HPGDS | |
| SCHEMBL1785268 | 0.84 | HTR2B (0.59) | HTR2BHDAC1HDAC8HDAC6ACHE | |
| Hydrochloric Acid SCHEMBL6821751 | 0.84 | HPGDS (0.71) | HDAC1HDAC8HDAC6TDP1ACHE | |
| SCHEMBL3612948 | 0.83 | HDAC1 (0.59) | HTR2BHDAC1HDAC8HDAC6TDP1 | |
| SCHEMBL999473 | 0.83 | HDAC1 (0.69) | HTR2BHDAC1HDAC8HDAC6ACHE | |
| SCHEMBL10334420 | 0.83 | ALDH1A1 (0.73) | HTR2BHDAC1HDAC8HDAC6ACHE | |
| SCHEMBL1249544 | 0.83 | RAB9A (0.66) | HTR2BHDAC1HDAC8HDAC6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | claimed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR2B 3364/4885HDAC1 2416/4885HDAC8 1203/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HTR2B 4692/4885HDAC1 1233/4885HDAC8 1901/4885 |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | HTR2B 1046/4885HDAC1 1391/4885HDAC8 2917/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | HTR2B 4313/4885HDAC1 235/4885HDAC8 298/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | HTR2B 1137/4885HDAC1 2731/4885HDAC8 4399/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR2B 1659/4885HDAC1 3273/4885HDAC8 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.